Sopharma AD (WSE:SPH)

Market Cap	2.70B
Revenue (ttm)	4.86B
Net Income (ttm)	189.23M
Shares Out	n/a
EPS (ttm)	0.36
PE Ratio	14.28
Forward PE	n/a
Dividend	0.23 (1.80%)
Ex-Dividend Date	Jul 10, 2025

Volume	2,082
Average Volume	597
Open	12.75
Previous Close	12.75
Day's Range	12.75 - 12.75
52-Week Range	1.67 - 16.00
Beta	-0.16
RSI	51.65
Earnings Date	Jul 30, 2025

About Sopharma AD

Sopharma AD produces, distributes, and exports pharmaceutical products in Europe, Bulgaria, and internationally. It offers Carsil to treat liver disease; Tempalgin, a painkiller; Analgin, a pain reliever; Tabex, a drug used for smoking secession; Tribestan, a drug used for stimulation of the male reproductive system; Broncholytin, which is used to suppress cough; Nivalin for use in the peripheral nervous system; Methylprednisolon for severe allergies and life-threatening conditions; Vitamin C; Valeriana to reduce the stress; and medical devices...

• Industry: Medical Distribution
• Sector: Healthcare
• Founded: 1933
• Employees: 5,599
• Stock Exchange: Warsaw Stock Exchange
• Ticker Symbol: SPH

Financial Performance

In 2024, Sopharma AD's revenue was 2.14 billion, an increase of 13.27% compared to the previous year's 1.89 billion. Earnings were 77.85 million, a decrease of -18.89%.

Financial numbers in BGN